SCHEDULE 13G/A: 8VC Entities and Joe Lonsdale Maintain 1% Stake in Senti Biosciences

8VC Fund I, L.P., 8VC Entrepreneurs Fund I, L.P., 8VC GP I, LLC, and Joe Lonsdale have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 253,755 shares, representing 1% of Senti Biosciences, Inc.'s common stock.

Summary

• 8VC Fund I, L.P. beneficially owns 249,827 shares of Senti Biosciences, Inc. common stock, representing 1% of the class.
• 8VC Entrepreneurs Fund I, L.P. beneficially owns 3,928 shares of Senti Biosciences, Inc. common stock, representing 0% of the class.
• 8VC GP I, LLC, as the general partner of both funds, beneficially owns an aggregate of 253,755 shares, representing 1% of the class.
• Joe Lonsdale, as the sole managing member of 8VC GP I, LLC, also beneficially owns 253,755 shares, representing 1% of the class, with sole voting and dispositive power.
• The beneficial ownership percentage is based on 26,004,366 shares of Common Stock outstanding as of March 18, 2025, as reported by Senti Biosciences, Inc. in its annual report on Form 10-K for the year ended December 31, 2024.
• This filing is Amendment No. 1 to the original Schedule 13G filed on February 8, 2023.
• The securities were not acquired for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, indicating no significant positive or negative sentiment regarding the company's operations or prospects.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a continued, albeit small, passive investment by venture capital entities in Senti Biosciences, Inc., a biotechnology company. Such filings are standard disclosures for institutional investors holding a certain percentage of a company's stock, reflecting ongoing portfolio management rather than a specific industry trend.

Stakeholder Impact

• The filing indicates that 8VC entities and Joe Lonsdale continue to hold a 1% stake in Senti Biosciences, Inc., which is a minor, passive investment and is unlikely to have a direct material impact on shareholders, employees, customers, suppliers, or creditors.
• The disclosure provides transparency regarding a significant investor's position, which is generally positive for market transparency.

Key Dates

Keywords

Senti Biosciences Inc., 8VC Fund I L.P., 8VC Entrepreneurs Fund I L.P., 8VC GP I LLC, Joe Lonsdale, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Venture Capital